Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human papillomavirus type 16 (HPV16) protein E6 is a viral oncoprotein encoded by the early region of the HPV16 genome, one of the most prevalent high-risk HPVs causally related to anogenital and head & neck malignancies. E6 acts primarily as an oncoprotein, playing a major role in cellular transformation by binding to host ubiquitin-protein ligase UBE3A/E6AP and targeting tumor suppressors TP53 (p53) and TP73 for proteasomal degradation. It also promotes degradation of other cellular targets and inhibits immune responses.
Current research focuses on directly inhibiting or silencing E6 oncoproteins as potential therapies against cervical cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus Type 16 Protein E6 (E6).